Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study

Hang Quach, MD, Simon J Harrison, MBBS MRCP (UK) PhDFRCPath (UK) FRACP, Je-Jung Lee, MD PhD, Nichloas Murphy, MBBS, FRACP, FRCPA, Jae Hoon Lee, MD PhD, Kim Kihyun, MD, Jane Estell, FRACP, Noemi Horvath, MB ChB FRACP FRCPA, Richard Eek, FRACP., Bradley Augustson, MBBS FRACP FRCPA, Philip Campbell, MBBS, Rajeev Rajagopal, FRACP, Soo-Mee Bang, MDPhD, Jeffrey SY Huang, MD, PhD, Yoon Sung Soo, MD PhD, Belinda Butcher, BSci, MBiostat, PhD, Brian G.M. Durie, MD, Wee Joo Chng, MD PhD

Blood (2020) 136 (Supplement 1): 39–40.

https://doi.org/10.1182/blood-2020-139174

Published: 2020

Journal Articles

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Kim Huynh, BBiomedSc (Hons), PhD, Naomi Aoki, MSc, BSc, Kihyun Kim, MD PhD, Wee Joo Chng, MD PhD, Gin Gin Gan, MBBS, MRCP, FRCP, Chang-Ki Min, MD PhD, Je-Jung Lee, MD PhD, Yeow Tee Goh, MBBS, Cameron Wellard, Zoe McQuilten, MBBS, PhD, Elizabeth M. Moore, PhD, Erica M. Wood, MBBS, FRACP, FRCPA, Andrew Spencer, MBBS, FRACP, FRCPA, DM

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136896

Published: 2020

Journal Articles

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

Kihyun Kim, MD PhD, Jin Seok Kim, MD PhD, Sung-Soo Yoon, MD PhD, Dok-Hyun Yoon, MD PhD, HyeonSeok Eom, MD PhD, Je-Jung Lee, MD PhD, Hyeonwoo Yim, MD PhD, Misun Park, MS, Hojoon Lee, DRPH,MDMPH,PhD, Chang Ki Min, MD PhD

Blood (2020) 136 (Supplement 1): 14.

https://doi.org/10.1182/blood-2020-136242

Published: 2020

Journal Articles

Clinical Impact of Enrollment of Clinical Trial in Multiple Myeloma; Single Center Experience

Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Ga-Young Song, Deok-Hwan Yang, MD PhD, Jae-Sook Ahn, MD PhD, Hyeoung-Joon Kim, MD PhD, Je-Jung Lee, MD PhD

Blood (2019) 134 (Supplement_1): 5525.

https://doi.org/10.1182/blood-2019-127889

Published: 2019

Journal Articles

Genomic Profiles and Subset Characterization of CD8 + terminally Differentiated Effector Memory (T EMRA ) Cells from Cancer Patients

Deok-Hwan Yang, MD PhD, Jae-Sook Ahn, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Je-Jung Lee, MD PhD, Hyeoung-Joon Kim, MD PhD, Young Rok Do, PhDMD, Sang Yun Song, MD PhD, Ga-Young Song, Hyeong Jong Kim, MD, Theresa Kim

Blood (2019) 134 (Supplement_1): 2329.

https://doi.org/10.1182/blood-2019-126533

Published: 2019

Journal Articles

Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era

Ji Hyun Lee, MD PhD, Sung-Hyun Kim, MD PhD, Ho-Sup Lee, MD PhD, Sung-Soo Yoon, MD PhD, Dong-Yeop Shin, MD PhD, Ja Min Byun, Je-Jung Lee, MD PhD, Sung-Hoon Jung, MD, Chang-Ki Min, MD PhD, Hyo Jung Kim, MD PhD, Byeong Seok Sohn, MD PhD, Sung Hwa Bae, MD, Lee Gyeong-Won, Sungwoo Park, MD, Young Rok Do, PhDMD, Hyun Jung Lee, MD, Min Kyoung Kim, Yoo Jin Lee, MD PhD

Blood (2019) 134 (Supplement_1): 4372.

https://doi.org/10.1182/blood-2019-127707

Published: 2019

Journal Articles

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

Ho Sup Lee, MD PhD, Chang-Ki Min, MD PhD, Kihyun Kim, MD, Seok Jin Kim, MD PhD, Je-Jung Lee, MD PhD, Inho Kim, MD PhD, Sung-Soo Yoon, MD PhD, Jin Seok Kim, MD PhD, Hyeon-Seok Eom, MD PhD, Dok Hyun Yoon, MD PhD, Cheolwon Suh, Ho-Jin Shin, MD PhD, Yeung-Chul Mun, MD, Min Kyoung Kim, MD PhD, Sung-Nam Lim, MD, Chul Won Choi, Hye Jin Kang, MD PhD

Blood (2019) 134 (Supplement_1): 3114.

https://doi.org/10.1182/blood-2019-122404

Published: 2019

Journal Articles

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Je-Jung Lee, MD PhD, Tan-Huy Chu, Manh-Cuong Vo, Hye-Sung Park, Thangaraj Jaya Lakshmi, Seo-Yeon Ahn, MD, Ga-Young Song, Sung-Hoon Jung, MD, Hyeoung-Joon Kim, MD PhD

Blood (2019) 134 (Supplement_1): 1819.

https://doi.org/10.1182/blood-2019-127964

Published: 2019

Journal Articles

Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature As a High Risk Profile for Leukemic Transformation

Joon Ho Moon, MD, Taehyung Kim, MSc, Jae-Sook Ahn, MD PhD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Yoojin Lee, MD PhD, Sang Kyun Sohn, MD PhD, Hyeoung-Joon Kim, MD PhD, Zhaolei Zhang, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 4361.

https://doi.org/10.1182/blood-2018-99-116241

Published: 2018

Journal Articles

Diagnostic Accuracy of Immunoglobulin Heavy Chain Rearrangement, FDG-PET/CT and Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Diffuse Large B Cell Lymphoma

Seung-Yeon Jung, Sung-Hoon Jung, MD, Seo-Yeon Ahn, MD, Je-Jung Lee, MD PhD, Hyeoung-Joon Kim, MD PhD, Jun Hyung Lee, MD, Myung Geun Shin, MD PhD, Su Woong Yoo, Deok-Hwan Yang, MD PhD

Blood (2018) 132 (Supplement 1): 4236.

https://doi.org/10.1182/blood-2018-99-116398

Published: 2018

Journal Articles

18 f-FDG PET/CT and the Revised International Staging System Are More Discriminating of Survival Outcomes in Newly Diagnosed Multiple Myeloma

Sung-Hoon Jung, MD, Seong Young Kwon, Jung-Joon Min, Hee Seung Bom, Seo-Yeon Ahn, MD, Seung-Yeon Jung, Seung-Shin Lee, MD, Moo-Rim Park, MD, Deok-Hwan Yang, MD, Jae-Sook Ahn, MD PhD, Hyeoung-Joon Kim, MD PhD, Je-Jung Lee, MD PhD

Blood (2018) 132 (Supplement 1): 4483.

https://doi.org/10.1182/blood-2018-99-112354

Published: 2018

Journal Articles

Prognostic Significance of FDG-PET/CT on Determining Upfront Autologous Stem Cell Transplantation for the Treatment of Peripheral T Cell Lymphomas

Seo-Yeon Ahn, MD, Seung-Yeon Jung, Sung-Hoon Jung, MD, Jae-Sook Ahn, MD PhD, Je-Jung Lee, MD PhD, Hyeoung-Joon Kim, MD PhD, Sae-Ryung Kang, MD, Yeon-Hee Han, MD, Jae-Yong Kwak, MD PhD, Ho-Young Yhim, MD PhD, Deok-Hwan Yang, MD PhD

Blood (2018) 132 (Supplement 1): 1632.

https://doi.org/10.1182/blood-2018-99-118168

Published: 2018

Journal Articles

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MD PhD, Zhaolei Zhang, PhD, Hyeoung-Joon Kim, MD PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 2669.

https://doi.org/10.1182/blood-2018-99-112037

Published: 2018

Journal Articles

Enhancement of Antitumor Immunity Using Dendritic Cells Combined with Lenalidomide and Programmed Death Ligand-1 Blockade in Multiple Myeloma Mouse Model

Je-Jung Lee, MD PhD, Manh-Cuong Vo, Sung-Hoon Jung, MD, Tan-Huy Chu, Hyun-Ju Lee, Thangaraj Jaya Lakshmi, Hyeoung-Joon Kim, MD PhD

Blood (2018) 132 (Supplement 1): 3194.

https://doi.org/10.1182/blood-2018-99-112359

Published: 2018

Journal Articles

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Yoojin Lee, MD PhD, Kihyun Kim, MD PhD, Sang Kyun Sohn, MDPhD, Dongwon Back, MD, Joon Ho Moon, MD, Je-Jung Lee, MD PhD, Jae-Cheol Jo, MD, Won-Sik Lee, MD, Ho-Jin Shin, MD PhD, Sung-Hyun Kim, MD PhD, Ji Hyun Lee, MD PhD, Sung Hwa Bae, MD, Min Kyoung Kim, MD PhD, Ho Sup Lee, MD, Chang-Ki Min, MD PhD

Blood (2018) 132 (Supplement 1): 3252.

https://doi.org/10.1182/blood-2018-99-113229

Published: 2018

Journal Articles

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, MD PhD, Marc S. Tyndel, B. Eng, Seung-Shin Lee, MD, Seo-Yeon Ahn, MD, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Ja-yeon Lee, MSc, Yoojin Lee, MDPhD, Sang Kyun Sohn, MDPhD, Hyeoung-Joon Kim, MD PhD, Zhaolei Zhang, PhD, Dennis Dong Hwan Kim, MD PhD

Blood (2018) 132 (Supplement 1): 1391.

https://doi.org/10.1182/blood-2018-99-112906

Published: 2018

Journal Articles

Clinical and Genetic Relevance of Somatic Mutations in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Patients Using Serial Sequencing

Taehyung Kim, MSc, Joon Ho Moon, MD, Jae-Sook Ahn, Marc S. Tyndel, Yeo-Kyeoung Kim, Seung-Shin Lee, MD, Seo-Yeon Ahn, Sung-Hoon Jung, MD, Deok-Hwan Yang, MD PhD, Je-Jung Lee, MD PhD, Seunghyun Choi, PhD, Yoojin Lee, MD, Sang Kyun Sohn, MDPhD, Yoo Hong Min, MD PhD, June-Won Cheong, MDPhD, Hyeoung-Joon Kim, Zhaolei Zhang, PhD, Dennis (Dong-Hwong) Kim, MD PhD

Blood (2017) 130 (Supplement 1): 3955.

https://doi.org/10.1182/blood.V130.Suppl_1.3955.3955

Published: 2017

Journal Articles

Multimodality Targeting of Dendritic Cell Vaccination Combined with Immunomodulatory Drug and Immune Checkpoint Blockade Has Synergistically Induced a Marked Tumor Regression By Modulating Tumor Microenvironment in a Murine Myeloma Model

Manh-Cuong Vo, Hyun-Ju Lee, Sung-Hoon Jung, MD, Thangaraj Jaya Lakshmi, Hye-Sung Park, Tan-Huy Chu, Hyeoung-Joon Kim, Je-Jung Lee, MD PhD

Blood (2017) 130 (Supplement 1): 5453.

https://doi.org/10.1182/blood.V130.Suppl_1.5453.5453

Published: 2017

Journal Articles

Dendritic Cell Vaccination Combined with Pomalidomide and Dexamethasone Ameliorated Antitumor Immunity By Skewing Immuno-Suppressive Status Toward Immuno-Supportive Status in a Murine Myeloma Model

Sung-Hoon Jung, MD, Seoyun Yang, Hyun-Ju Lee, Manh-Cuong Vo, Thangaraj Jaya Lakshmi, Hye-Sung Park, Tan-Huy Chu, Hyeoung-Joon Kim, Je-Jung Lee, MD PhD

Blood (2017) 130 (Supplement 1): 5454.

https://doi.org/10.1182/blood.V130.Suppl_1.5454.5454

Published: 2017

Journal Articles

Cytoplasmic Transduction Peptide-Fused Recombinant Tumor-Associated Antigens Elicit Potent Myeloma-Specific Cytotoxic T Lymphocytes By Loading Onto Dendritic Cells: Implications of Feasible Tumor Antigens for Clinical Application Against Multiple Myeloma

Hyun-Ju Lee, Sung-Hoon Jung, MD, Manh-Cuong Vo, Thangaraj Jaya Lakshmi, Hye-Sung Park, Tan-Huy Chu, Hyeoung-Joon Kim, Je-Jung Lee, MD PhD

Blood (2017) 130 (Supplement 1): 5455.

https://doi.org/10.1182/blood.V130.Suppl_1.5455.5455

Published: 2017

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Carfilzomib Thalidomide and Dexamethasone Is Safe and Effective in the Treatment of Relapsed/Refractory Multiple Myeloma: An Open Label Phase II Australasian Leukaemia and Lymphoma Group (ALLG) MM 018/ Asian Myeloma Network (AMN) 002 Study

The Asia-Pacific Myeloma and Related Diseases Registry: Preliminary Results of Real-World Treatment Patterns and Clinical Outcomes

Clinical Course of High-Risk Multiple Myeloma Patients in Korea: A Multicenter Retrospective Study

Clinical Impact of Enrollment of Clinical Trial in Multiple Myeloma; Single Center Experience

Genomic Profiles and Subset Characterization of CD8 + terminally Differentiated Effector Memory (T EMRA ) Cells from Cancer Patients

Prognostic Implication of Inflammatory Factor-Based Staging System in Multiple Myeloma in the New Agent Era

Pomalidomide, Cyclophosphamide, and Dexamethasone for Elderly, Transplant-Ineligible Patients with Relapsed and/or Refractory Multiple Myeloma Who Had Failed Treatment with Lenalidomide and Bortezomib: A Study of the Korean Multiple Myeloma Working Party (KMMWP-164 study)

A Combination Therapy with Dendritic Cells, Pomalidomide and Programmed Death-Ligand 1 Blockade Exerts a Potent Antitumor Immunity in a Murine Model of Multiple Myeloma

Identification of High Risk Group for Leukemic Transformation in Higher Risk MDS Patients Using Targeted RNA-Sequencing: Hematopoietic Stem Cell Signature As a High Risk Profile for Leukemic Transformation

Diagnostic Accuracy of Immunoglobulin Heavy Chain Rearrangement, FDG-PET/CT and Unilateral Bone Marrow Trephination for Detecting Bone Marrow Involvement in Diffuse Large B Cell Lymphoma

18 f-FDG PET/CT and the Revised International Staging System Are More Discriminating of Survival Outcomes in Newly Diagnosed Multiple Myeloma

Prognostic Significance of FDG-PET/CT on Determining Upfront Autologous Stem Cell Transplantation for the Treatment of Peripheral T Cell Lymphomas

RNA Sequencing-Based Measurement of Fusion-Transcript for Minimal Residual Disease (MRD) Monitoring in Core-Binding Factor Acute Myeloid Leukemia (CBF-AML)

Enhancement of Antitumor Immunity Using Dendritic Cells Combined with Lenalidomide and Programmed Death Ligand-1 Blockade in Multiple Myeloma Mouse Model

Benefit of Two Additional Cycles of Bortezomib/Thalidomide/Dexamethasone (VTD) Induction Therapy Compared to Four Cycles of VTD for Newly Diagnosed Multiple Myeloma

Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)

Clinical and Genetic Relevance of Somatic Mutations in Core Binding Factor (CBF) Acute Myeloid Leukemia (AML) Patients Using Serial Sequencing

Multimodality Targeting of Dendritic Cell Vaccination Combined with Immunomodulatory Drug and Immune Checkpoint Blockade Has Synergistically Induced a Marked Tumor Regression By Modulating Tumor Microenvironment in a Murine Myeloma Model

Dendritic Cell Vaccination Combined with Pomalidomide and Dexamethasone Ameliorated Antitumor Immunity By Skewing Immuno-Suppressive Status Toward Immuno-Supportive Status in a Murine Myeloma Model

Cytoplasmic Transduction Peptide-Fused Recombinant Tumor-Associated Antigens Elicit Potent Myeloma-Specific Cytotoxic T Lymphocytes By Loading Onto Dendritic Cells: Implications of Feasible Tumor Antigens for Clinical Application Against Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only